Меню
Набор скоро начнётся NCT07211308

Open and Closed Loop DTM SCS in Patients With PSPS Type 2: ENDLESS Study

Наблюдательное Persistent Spinal Pain Syndrome Type 2 Failed Back Surgery Syndrome Failed Neck Surgery Syndrome

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
В протоколе указаны: Spinal Cord Stimulation.
Кому может быть актуально
Состояния в реестре: Persistent Spinal Pain Syndrome Type 2, Failed Back Surgery Syndrome, Failed Neck Surgery Syndrome. Базовые параметры: Без ограничений · Все.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
Бельгия
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →
Официальное название

Open and Closed Loop Differential Target Multiplexed Spinal Cord Stimulation in Patients With Persistent Spinal Pain Syndrome Type II: a European Multicenter Cohort Study (ENDLESS)

Обзор

Evaluation of the effectiveness of differential target multiplexed spinal cord stimulation for treatment of Persistent Spinal Pain Syndrome Type II (PSPS-T2). Identification of clinical effective parameters concerning frequency, pulse duration, amplitude and battery consumption/recharge frequency and safety evaluation.

Вмешательства

  • Устройство Spinal Cord Stimulation
    Differential target multiplexed stimulation

Первичные конечные точки

  • Overall pain intensity [Срок оценки: The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months]
Вторичные конечные точки (12)
  • Pain intensity for the lower back and leg pain or neck and arm pain component [Срок оценки: The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months]
  • Medication use [Срок оценки: The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months]
  • Negative affect [Срок оценки: The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months]
  • Functional disability [Срок оценки: The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months]
  • Health related quality of life [Срок оценки: The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months]
  • Patient global impression of change [Срок оценки: Evaluated at 1 month, 6 months and 12 months of DTM SCS]
  • Clinical holistic responder status [Срок оценки: The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months]
  • Work status [Срок оценки: The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months]
  • Pain catastrophizing [Срок оценки: The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months]
  • Anxiety and Depression [Срок оценки: The change between the baseline screening and the evaluation 1 month after DTM stimulation, 6 months and 12 months]
  • Patient expectations concerning SCS [Срок оценки: Evaluated at baseline visit]
  • Patient unwanted stimulation awareness and satisfaction about the therapy [Срок оценки: Evaluated at 1 month, 6 months and 12 months of DTM SCS]

Критерии участия

Критерии включения

  • having chronic pain as a result of PSPS-T2 that exists for at least 6 months with at least moderate pain intensity (4 or higher measured on numeric rating scale (NRS) or 31mm or higher measured on visual analogue scale (VAS) for the dominant pain location.
  • being offered treatment with DTM SCS
  • being at least 18 years old

Критерии исключения

  • Expected inability of patients to properly operate the SCS system
  • History of coagulation disorders, lupus erythematosus, diabetic neuropathy
  • Active malignancy
  • Addiction to drugs and/or alcohol (more than 5 units /day)
  • Evidence of an active disruptive psychiatric disorder or other known condition significant enough to impact perception of pain, compliance to intervention and/or ability to complete questionnaires, as determined by the investigator
  • Immune deficiency (e.g. HIV positive, immunosuppressiva)
  • Life expectancy < 1 year
  • Local infection or other skin disorder at site of incision
  • Pregnancy
  • Other implanted active medical device

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Модель наблюдения
Когортное

Центры проведения

Бельгия · 2 центра
  • UZ Brussel — Brussels
  • Vitaz — Sint-Niklaas

Идентификаторы

NCT: NCT07211308 · ENDLESS

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗